Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Par_Pharmaceutical
Paladin Labs |
| gptkbp:businessModel |
gptkb:public_company
|
| gptkbp:CEO |
Blaise Coleman
|
| gptkbp:country_of_incorporation |
gptkb:Ireland
|
| gptkbp:delistedDate |
gptkb:NASDAQ_(2023)
|
| gptkbp:filedForBankruptcy |
2022
|
| gptkbp:founded |
1997
|
| gptkbp:headquarters_location |
gptkb:Dublin,_Ireland
|
| gptkbp:headquartersLocation |
gptkb:Malvern,_Pennsylvania,_USA
|
| https://www.w3.org/2000/01/rdf-schema#label |
Endo International
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:involves |
opioid litigation
|
| gptkbp:notableProduct |
gptkb:Percocet
Supprelin LA Vasostrict Opana ER XIAFLEX |
| gptkbp:numberOfEmployees |
~3,000 (2021)
|
| gptkbp:parentCompany |
Endo Health Solutions Inc.
|
| gptkbp:products |
generic drugs
branded pharmaceuticals specialty pharmaceuticals |
| gptkbp:stockSymbol |
ENDP
|
| gptkbp:tradedOn |
NASDAQ: ENDP
|
| gptkbp:website |
https://www.endo.com/
|
| gptkbp:bfsParent |
gptkb:PhRMA
|
| gptkbp:bfsLayer |
6
|